113
Participants
Start Date
July 2, 2019
Primary Completion Date
February 8, 2022
Study Completion Date
February 8, 2022
RMC-4630
RMC-4630 for oral administration
Cobimetinib
Cobimetinib for oral administration
Drug: Osimertinib
Osimertinib for oral administration
Memorial Sloan Kettering Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax
Winship Cancer Institute, Emory University, Atlanta
Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville
Ohio State University, Columbus
Karmanos Cancer Institute, Detroit
University of Wisconsin, Madison
Northwestern University, Chicago
University of Oklahoma - Stephenson Cancer Center, Oklahoma City
Dell Seton Medical Center at University of Texas, Austin
University of Colorado Cancer Center, Aurora
Honor Health Research Institute, Scottsdale
City of Hope, Duarte
UC Irvine - Chao Family Comprehensive Cancer Center, Orange
UC San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
UC Davis Comprehensive Cancer Center, Sacramento
Providence Cancer Institute, Franz Clinic, Portland
Seoul National University Hospital, Seoul
Dana Farber Cancer Institute, Boston
Severance Hospital Yonsei University Health System, Seoul
Samsung Medical Center - PPDS, Seoul
Collaborators (1)
Sanofi
INDUSTRY
Revolution Medicines, Inc.
INDUSTRY